• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝素辅因子II的缺失诱变:确定凝血酶抑制丝氨酸蛋白酶抑制剂的最小尺寸

Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin.

作者信息

Sheffield W P, Blajchman M A

机构信息

Canadian Red Cross Blood Services, McMaster University Medical Centre, Hamilton, Ontario.

出版信息

FEBS Lett. 1995 May 29;365(2-3):189-92. doi: 10.1016/0014-5793(95)00468-o.

DOI:10.1016/0014-5793(95)00468-o
PMID:7781777
Abstract

Heparin cofactor II (HCII) is a 66 kDa plasma glycoprotein that belongs to the serpin superfamily of protease inhibitors. Its natural target is thrombin. HCII inhibits thrombin in both a progressive reaction, and in an accelerated reaction catalyzed by a glycosaminoglycan, dermatan sulphate (DS). Both modes of inhibition result in the formation of a stable, denaturation-resistant complex. Using a cDNA clone encoding rabbit HCII recently isolated and characterized in our laboratory, we have employed deletion mutagenesis to identify amino-terminal regions of the molecular which are essential to the progressive reaction. PCR was employed to produce four deletion constructs: delta 58, delta 81, delta 106, and delta 169, all in an in vitro transcription vector plasmid background. Transcription of the full-length construct, and of the four deletion constructs, followed by in vitro translation in rabbit reticulocyte lysate, was used to produce the corresponding HCII-related polypeptides. The delta 106 and delta 169 mutants failed to react with thrombin, even in the presence of DS. In contrast, the delta 58 and delta 82 mutants retained the ability to form complexes with thrombin, although the rate of complex formation was decreased for the latter mutant compared to the full-length recombinant HCII; no acceleration of complex formation in the presence of 20 micrograms/ml DS was noted for either truncated recombinant HCII. Alignment of the rabbit HCII primary structure with secondary structural elements found in alpha 1 antitrypsin and other serpins showed that the non-functional delta 106 mutant lacks helix A, while the functional delta 82 mutant contains this element. Our results suggest that helix A is an essential part of a functional serpin, and define the limits of the amino-terminal region of HCII which is not essential for thrombin inhibition.

摘要

肝素辅因子II(HCII)是一种66 kDa的血浆糖蛋白,属于丝氨酸蛋白酶抑制剂超家族。其天然靶点是凝血酶。HCII在渐进反应以及由糖胺聚糖硫酸皮肤素(DS)催化的加速反应中均能抑制凝血酶。两种抑制模式都会导致形成稳定的、抗变性的复合物。利用我们实验室最近分离并鉴定的编码兔HCII的cDNA克隆,我们采用缺失诱变来确定分子中对渐进反应至关重要的氨基末端区域。使用PCR产生了四个缺失构建体:delta 58、delta 81、delta 106和delta 169,均处于体外转录载体质粒背景中。全长构建体以及四个缺失构建体的转录,随后在兔网织红细胞裂解物中进行体外翻译,用于产生相应的与HCII相关的多肽。delta 106和delta 169突变体即使在存在DS的情况下也无法与凝血酶反应。相比之下,delta 58和delta 82突变体保留了与凝血酶形成复合物的能力,尽管与全长重组HCII相比,后者突变体形成复合物的速率有所降低;对于任何一种截短的重组HCII,在存在20微克/毫升DS的情况下均未观察到复合物形成加速。将兔HCII一级结构与α1抗胰蛋白酶和其他丝氨酸蛋白酶抑制剂中的二级结构元件进行比对,结果表明无功能的delta 106突变体缺乏螺旋A,而有功能的delta 82突变体含有该元件。我们的结果表明螺旋A是功能性丝氨酸蛋白酶抑制剂的重要组成部分,并确定了HCII氨基末端区域对凝血酶抑制并非必需的界限。

相似文献

1
Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin.肝素辅因子II的缺失诱变:确定凝血酶抑制丝氨酸蛋白酶抑制剂的最小尺寸
FEBS Lett. 1995 May 29;365(2-3):189-92. doi: 10.1016/0014-5793(95)00468-o.
2
Molecular cloning and expression of rabbit heparin cofactor II: a plasma thrombin inhibitor highly conserved between species.兔肝素辅因子II的分子克隆与表达:一种在物种间高度保守的血浆凝血酶抑制剂。
Thromb Haemost. 1994 Jun;71(6):778-82.
3
The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.作为凝血酶外位点1配体发挥最大效力,肝素辅因子II完整的N端延伸部分是必需的。
BMC Biochem. 2013 Mar 7;14:6. doi: 10.1186/1471-2091-14-6.
4
Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.对肝素辅因子II假定的糖胺聚糖结合位点中的精氨酸103和赖氨酸185进行定点诱变。
J Biol Chem. 1990 Jan 5;265(1):286-91.
5
Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.用肝素辅因子II的反应中心环完全或部分替代α-1-蛋白酶抑制剂的反应中心环:最大程度抑制凝血酶需要P1精氨酸。
Biochemistry. 2004 Nov 23;43(46):14864-72. doi: 10.1021/bi048833f.
6
The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.在存在糖胺聚糖的情况下,肝素辅因子II的N端酸性结构域介导对α-凝血酶的抑制作用。
J Biol Chem. 1991 Oct 25;266(30):20223-31.
7
Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.在肝素辅因子II的反应位点将亮氨酸444替换为精氨酸可提高凝血酶抑制速率。
J Biol Chem. 1990 Apr 5;265(10):5623-8.
8
Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.糖胺聚糖依赖性丝氨酸蛋白酶抑制剂蛋白C抑制剂和肝素辅因子II对凝血酶阴离子结合外位点-2突变体的抑制作用。
Thromb Res. 2002 Jul 15;107(1-2):67-73. doi: 10.1016/s0049-3848(02)00180-9.
9
Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions.
Biochim Biophys Acta. 1999 Apr 12;1431(1):148-56. doi: 10.1016/s0167-4838(99)00051-5.
10
Molecular mapping of the thrombin-heparin cofactor II complex.凝血酶-肝素辅因子II复合物的分子图谱
J Biol Chem. 2004 Oct 8;279(41):43237-44. doi: 10.1074/jbc.M406716200. Epub 2004 Aug 2.

引用本文的文献

1
Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.水蛭素变体 3 的 C 末端十三肽与 α1-蛋白酶抑制剂 M358R 的融合增加了丝氨酸蛋白酶抑制剂介导的凝血酶抑制速率。
BMC Biochem. 2013 Nov 11;14:31. doi: 10.1186/1471-2091-14-31.